Jordi Xiol

Jordi Xiol is a Partner at Ysios Capital, a leading Spanish venture capital firm focused on life sciences investments.1 Here's a comprehensive overview of his professional background and current role:

Professional Experience

Jordi Xiol joined Ysios Capital in 2019 as an Associate and was recently promoted to Partner in January 2023.1 In his current role, he is responsible for making and managing investments at the firm.2

Previous Work

Prior to joining Ysios Capital, Jordi worked at Vida Ventures in Boston, where he focused on investment opportunities in oncology, gene therapy, and ophthalmology.12

Education

Jordi has a strong background in science, particularly in biochemistry and molecular biology. He received education at the European Molecular Biology Laboratory.3

Current Responsibilities

As a Partner at Ysios Capital, Jordi's responsibilities include:

1. Identifying and evaluating investment opportunities in the life sciences sector1
2. Making and managing investments for the firm2
3. Serving on the boards of portfolio companies

Board Positions

Jordi currently holds the following board positions:

• Member of the board of directors at Northsea Therapeutics
• Member of the board of directors at Splice Bio
• Observer on the board of directors at Adcendo
• Observer on the board of directors at Cytoki1

Expertise

Jordi's expertise lies in the intersection of life sciences and venture capital. His background in molecular biology and experience in evaluating investment opportunities in areas such as oncology, gene therapy, and ophthalmology make him a valuable asset to Ysios Capital's team.12

Social Media Presence

Jordi maintains a professional presence on social media platforms:

• LinkedIn: His profile can be found under the username jordi-xiol-886398333
• Twitter: He uses the handle @jordixiol, where he describes himself as "Biotech VC @YsiosCapital | Molecular biologist"4

Jordi Xiol's promotion to Partner at Ysios Capital reflects his significant contributions to the firm and his expertise in identifying and evaluating promising investment opportunities in the life sciences sector.